Kitasato Y, et al. Metastatic Pulmonary Adenocarcinoma 13 Years After Curative Resection for Pancreatic Cancer: Report of a Case and Review of Japanese Literature. JOP. J Pancreas (Online) 2012 May 10; 13(3):296-300.
![Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer | Journal of Ovarian Research | Full Text Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer | Journal of Ovarian Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13048-020-00681-0/MediaObjects/13048_2020_681_Fig3_HTML.png)
Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer | Journal of Ovarian Research | Full Text
![Patient's level of tumor marker CA-125 before and after neoadjuvant CTX... | Download Scientific Diagram Patient's level of tumor marker CA-125 before and after neoadjuvant CTX... | Download Scientific Diagram](https://www.researchgate.net/publication/359622729/figure/fig2/AS:11431281086976221@1664416615285/Patients-level-of-tumor-marker-CA-125-before-and-after-neoadjuvant-CTX-logarithmic.png)
Patient's level of tumor marker CA-125 before and after neoadjuvant CTX... | Download Scientific Diagram
![Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance - ScienceDirect Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0960977620301120-gr3.jpg)
Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance - ScienceDirect
![Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance - ScienceDirect Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0960977620301120-gr2.jpg)
Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance - ScienceDirect
![The utility of the tumor markers CA15.3, CEA, CA-125 and CA19.9 in metastatic breast cancer | Breast Cancer Management The utility of the tumor markers CA15.3, CEA, CA-125 and CA19.9 in metastatic breast cancer | Breast Cancer Management](https://www.futuremedicine.com/cms/10.2217/bmt-2020-0015/asset/images/medium/figure1.gif)
The utility of the tumor markers CA15.3, CEA, CA-125 and CA19.9 in metastatic breast cancer | Breast Cancer Management
![IJMS | Free Full-Text | CA 19-9 Pancreatic Tumor Marker Fluorescence Immunosensing Detection via Immobilized Carbon Quantum Dots Conjugated Gold Nanocomposite IJMS | Free Full-Text | CA 19-9 Pancreatic Tumor Marker Fluorescence Immunosensing Detection via Immobilized Carbon Quantum Dots Conjugated Gold Nanocomposite](https://pub.mdpi-res.com/ijms/ijms-19-01162/article_deploy/html/images/ijms-19-01162-sch003.png?1570011465)
IJMS | Free Full-Text | CA 19-9 Pancreatic Tumor Marker Fluorescence Immunosensing Detection via Immobilized Carbon Quantum Dots Conjugated Gold Nanocomposite
![Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics](https://pubs.rsna.org/cms/10.1148/rg.2021210005/asset/images/medium/rg.2021210005.va.gif)